Skye Bioscience Chairman & CEO Punit Dhillon joins Natalie Stoberman from the Proactive newsroom to share the announcement of its SBI-100 OE glaucoma treatment receiving FDA authorization for an Investigational New Drug Application.
Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.
#proactiveinvestors #skyebioscience #OTCQB #SKYE #bioscience #glaucoma #fda #cannabis #cannabinoid
